Your browser doesn't support javascript.
Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed.
Feldmann, Marc; Maini, Ravinder N; Woody, James N; Holgate, Stephen T; Winter, Gregory; Rowland, Matthew; Richards, Duncan; Hussell, Tracy.
  • Feldmann M; Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Botnar Research Centre, Oxford OX3 7LD, UK. Electronic address: marc.feldmann@kennedy.ox.ac.uk.
  • Maini RN; Imperial College London, London, UK.
  • Woody JN; Laterell Venture Partners, San Francisco, CA, USA.
  • Holgate ST; Faculty of Medicine, Clinical and Experimental Sciences, Southampton General Hospital, Southampton, UK.
  • Winter G; Trinity College, Cambridge, UK.
  • Rowland M; Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.
  • Richards D; Oxford Clinical Trials Research Unit, Botnar Research Centre, Oxford, UK.
  • Hussell T; Lydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester, UK.
Lancet ; 395(10234): 1407-1409, 2020 05 02.
Article in English | MEDLINE | ID: covidwho-47401

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Clinical Trials as Topic / Tumor Necrosis Factor-alpha / Coronavirus Infections / Inflammation Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Humans Language: English Journal: Lancet Year: 2020 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Clinical Trials as Topic / Tumor Necrosis Factor-alpha / Coronavirus Infections / Inflammation Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Humans Language: English Journal: Lancet Year: 2020 Document Type: Article